Evidence map›Paper›PMID 36920936›Full record

ArticlePloS one2023

The effect of a novel AQP4 facilitator, TGN-073, on glymphatic transport captured by diffusion MRI and DCE-MRI.

Alaa Alghanimy, Conor Martin, Lindsay Gallagher, William M Holmes

Full text read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. The glymphatic system and glioblastoma.Brain : a journal of neurology · 2026
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Aquaporin-4 in Stroke and Brain Edema-Friend or Foe?International journal of molecular sciences · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. A Histopathologic Correlation Study Evaluating Glymphatic Function in Brain Tumors by Multiparametric MRI.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  16. Review
  17. Review
  18. Review
  19. Aquaporin-4 and Parkinson's Disease.International journal of molecular sciences · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alaa AlghanimyInstitute of Neuroscience and Psychology, College of Medicine, Veterinary and Life Science, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0002-0663-2389
Conor MartinInstitute of Neuroscience and Psychology, College of Medicine, Veterinary and Life Science, University of Glasgow, Glasgow, United Kingdom.
Lindsay GallagherInstitute of Neuroscience and Psychology, College of Medicine, Veterinary and Life Science, University of Glasgow, Glasgow, United Kingdom.
William M HolmesInstitute of Neuroscience and Psychology, College of Medicine, Veterinary and Life Science, University of Glasgow, Glasgow, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The glymphatic system is a low resistance pathway, by which cerebrospinal fluid enters the brain parenchyma along perivascular spaces via AQP4 channels. It is hypothesised that the resulting convective flow of the interstitial fluid provides an efficient mechanism for the removal of waste toxins from the brain. Therefore, enhancing AQP4 function might protect against neurodegenerative diseases such as Alzheimer's disease (AD), in which the accumulation of harmful proteins and solutes is a hallmark feature. Here, we test the effect of a putative AQP4 facilitator, TGN-073, on glymphatic transport in a normal rat brain by employing different MRI techniques. Surgical procedures were undertaken to catheterise the cisterna magna, thereby enabling infusion of the MRI tracer. Followed by the intraperitoneal injection of either TGN-073, or the vehicle. Using a paramagnetic contrast agent (Gd-DTPA) as the MRI tracer, dynamic 3D T1 weighted imaging of the glymphatic system was undertaken over two hours. Further, the apparent diffusion coefficient was measured in different brain regions using diffusion-weighted imaging (DWI). While physiological parameters and arterial blood gas analysis were monitored continuously. We found that rats treated with TGN-073 showed the distribution of Gd-DTPA was more extensive and parenchymal uptake was higher compared with the vehicle group. Water diffusivity was increased in the brain of TGN-073 treated group, which indicates greater water flux. Also, MRI showed the glymphatic transport and distribution in the brain is naturally heterogeneous, which is consistent with previous studies. Our results indicate that compounds such as TGN-073 can improve glymphatic function in the brain. Since glymphatic impairment due to AQP4 dysfunction is potentially associated with several neurological disorders such as AD, dementia and traumatic brain injury, enhancing AQP4 functionality might be a promising therapeutic target.

Indexed as

Gadolinium DTPAGlymphatic SystemAnimalsAquaporin 4BenzenesulfonamidesBrainDiffusion Magnetic Resonance ImagingMagnetic Resonance ImagingPyridinesRatsAqp4 protein, ratAquaporin 4BenzenesulfonamidesGadolinium DTPAPyridinesTGN-073

Identifiers

PMID36920936
PMCPMC10016657

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read45
table measurements read10
identifiers read5
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.